AzTrials
AzTrials

FastingNCT03098381

Alteration in Body Composition and Metabolic Profile During Ramadan Fasting in Healthy Men

An observational study of Fasting, run by Chulalongkorn University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

One of religious duties for all healthy adult Muslims is fasting during Ramadan, the ninth month of Islamic lunar calendar. In this month, Ramadan observance fasted (no food and drink) from dawn to dusk. Studies demonstrated daytime fasting may pose a positive significant effect on metabolic health. Read more about this study

Who is it for?
Ages 19 to 40 years, men only
Conditions the study is for
Fasting
How many people
27 participants
Where
No sites listed yet
Study dates
Jun 2016to Mar 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 40 years
  • Men only
  • Adult

Study population: 27 healthy men (19-31 years) Muslim

Who may be able to join

  • age 19-40 years
  • Muslim men
  • fasted completely during Ramadan
  • no known of any metabolic-related diseases.

Who cannot join

  • any diseases
  • intake of any medication and dietary supplement
  • smoking
  • alcohol drinking

About this study

Official title: Alteration in Body Composition and Metabolic Profile Without Changes on Serum Leptin and Adiponectin Levels During Ramadan Fasting in Healthy Men

One of religious duties for all healthy adult Muslims is fasting during Ramadan, the ninth month of Islamic lunar calendar. In this month, Ramadan observance fasted (no food and drink) from dawn to dusk. Studies demonstrated daytime fasting may pose a positive significant effect on metabolic health. Thus, this present study aimed to determine the effect of Ramadan fasting on body composition, metabolic profile, serum leptin and adiponectin levels in healthy men.

Read the detailed description

Outcome measurements were taken at before (baseline) and at the end of Ramadan (after Ramadan fasting) on body composition, metabolic profile (fasting plasma glucose, insulin, total cholesterol, HDL-c, LDL-c, triglycerides, and HOMA-IR), serum leptin and adiponectin, ratio of leptin to adiponectin in 27 healthy men (19-31 years) Muslim in Bangkok, Thailand.

Subjects Twenty-nine subjects fulfilled inclusion criteria including: age 19-40 years, Muslim men fasted completely, and no known of any metabolic-related diseases. Subjects with diseases and/or intake of any medication and dietary supplement, smoking, and alcohol drinking were excluded. After Ramadan fasting, 27 subjects completed the study.

The study protocol was approved by the Ethical Review Committee for Research Involving Human Research Participants, Health Science Group, Chulalongkorn University, Bangkok, Thailand (COA no. 136/2558).Written informed consent was obtained from all subjects prior to enrolling to the study. Subject's anonymity was preserved.

Study design Research visit was conducted at Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand at before (earlier days of Ramadan) and after (third week of Ramadan) to collect the outcome measurements including anthropometry, body composition, metabolic profile, serum leptin and adiponectin levels, and ratio of leptin to adiponectin. The dietary intake of 2 weekday and one weekend day and physical activity were recorded each week during Ramadan in food record booklet. Energy intake and macronutrients composition including carbohydrate, protein and fat will be analysed by registered dietitian.

Anthropometry and body composition measurements Weight, Body Mass Index (BMI), and percent body fat were measured at baseline (week-0) and the end of Ramadan fasting period (week-4). Body weight, and percent body fat mass were assessed using a constant current source with a high frequency current (50kHz, 500μA)-bioelectrical impedance analyzer (BIA) (MC-980MA body composition analyzer, TANITA corporation, Tokyo, JAPAN). The subject was requested to dress in light attire and bare feet. The 8 polar electrodes were positioned so that electric current was supplied from the electrodes on the tips of the toes of both feet and the fingertips of both hands, and voltage is measured on the heel of both feet and the near side of both hands. Body Mass Index (BMI) was calculated as weight/height2 (in kilograms per square meter). Waist and hip circumferences were measured by using a standard rounded tape at a point right above the iliac crest on the mid-axillary line at minimal respiration (for waist) and in a horizontal plane at the level of the maximal extension of the buttocks (for hip) to the nearest 1.0 cm.

Metabolic profile measurements Fasting blood samples were taken from vein puncture at before and after a period of Ramadan fasting. Separated serum samples were stored at - 80o C until analyses were performed. After withdrawal, blood samples were collected to determine the metabolic profile including plasma glucose, total cholesterol, high density lipoprotein-cholesterol (HDL-c), and triglycerides (TG) by enzymatic method while serum insulin levels were analyzed by Chemiluminescence. Low density lipoprotein-cholesterol (LDL-c) was estimated by using the Friedewald equation (LDL-c = [total cholesterol] - [HDL-c] - [TG]/5).22 Additionally, HOMA-IR was measured as fasting serum insulin (µIU/mL) x fasting plasma glucose (mmol/L)/22.5.23

Serum leptin and adiponectin measurements Serum leptin and adiponectin levels were assayed at the laboratory at Faculty of Allied Health Sciences, Chulalongkorn University. Serum leptin was measured using a commercially "Human Leptin Standard ABTS ELISA Development kit" (Peprotech, Inc., Rocky Hill, NJ, USA, Cat. no: 900-K90) at a wavelength of 405nm with correction set at 650nm, while serum adiponectin was measured using "Adiponectin (human) ELISA kit" (Enzo Life Sciences, Farmingdale, NY, USA, Cat. no: ALX-850-377) at a wavelength of 450nm with correction set at 630nm. Both serum leptin and adiponectin were measured by the enzyme-linked immunosorbent assay, and were carried out according to the manufacturer's procedure.

Statistical Analysis Data were expressed as frequency or percentage for descriptive; mean ± standard error mean (SEM), mean percentage change (% change) ± SEM for the continuous-normally distributed data; and median (range) for continuous-non normally distributed data. Paired student t-test, two related sample (Wilcoxon) test were employed for comparison of normally distributed and non-normally distributed data, respectively. Differences were considered as statistically significant for two-tailed of probability value or P less than 0.05. All analyses were performed using SPSS, version 16.0 (IBM, Chicago, IL, USA).

Conditions
Fasting
Medical subject headings
Fasting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. body composition

    fat mass changes after 1 month of ramadan fasting in 27 participants

    Measured: 1 months

Secondary outcomes (2)
  1. Metabolic profile

    cholesterol change after 1 month of ramadan fasting in 27 participants

    Measured: 1 month

  2. Serum leptin and adiponectin measurements

    concentrations of Leptin and Adiponectin changes after 1 month of ramadan fasting in 27 participants

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Mar 2017
  2. Study startJun 2016
  3. Primary completionSep 2016
  4. Study completionMar 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03098381
Sponsor's protocol ID
Nutrition and Dietetics Dept
Status last verified
Mar 2017
First submitted
15 Mar 2017
Last updated
31 Mar 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Schmidt J, Hotz HG, Foitzik T, Ryschich E, Buhr HJ, Warshaw AL, Herfarth C, Klar E. Intravenous contrast medium aggravates the impairment of pancreatic microcirculation in necrotizing pancreatitis in the rat. Ann Surg. 1995 Mar;221(3):257-64. doi: 10.1097/00000658-199503000-00007.

    PubMed 7717779

Questions about this trial

What is this clinical trial studying?

An observational study of Fasting, run by Chulalongkorn University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

body composition (time frame: 1 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03098381, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in